Scarica l'app Stockscreener
31.31
1.42%
-0.45
Pre-mercato:
31.13
-0.18
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
VKTX Stock Slips Overnight: Investors Pin Hopes On Fresh Weight-Loss Data As Pfizer Joins Eli Lilly, Novo In GLP-1 War - Stocktwits
Obesity drug pill data and Phase 3 trial details head to ECO 2026 - Stock Titan
Viking Therapeutics: Market Betting On Big Upside Through 2030 (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 - ChartMill
Discipline and Rules-Based Execution in VKTX Response - Stock Traders Daily
VKTX Q1 earnings miss on higher phase 3 development costs - MSN
Dark Horse in the Weight-Loss Drug Arena? Viking Therapeutics Has Potential Upside of Over 200% - NAI500
Here's exactly why Wall Street thinks Viking Therapeutics stock could soar 207% over the next 12 months - MSN
Viking Therapeutics faces timeline risk, but upside could be huge - MSN
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months - The Motley Fool
Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port - Benzinga
CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $107 - Moomoo
Viking Therapeutics Stock Surges on Bold Analyst Call - TipRanks
The $30 Stock Wall Street Values at $93? - Bitget
Viking Therapeutics: InvestingPro’s overvalued call proved prescient By Investing.com - Investing.com Australia
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss - Yahoo Finance
VKTX Shares Drop After Hours On Larger Q1 Losses But Retail Eyes The Launch Of Its Obesity Pipeline - Stocktwits
Viking Therapeutics, Inc. (VKTX) suffers a larger drop than the general market: Key insights - MSN
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - Moomoo
A Look At Viking Therapeutics (VKTX) Valuation As Phase 3 Obesity Program Reaches Key Enrollment Milestones - simplywall.st
Viking Therapeutics (VKTX) Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment CompletionHas The Bull Case Changed? - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Stock (VKTX) Opinions on Q1 Earnings and Phase 3 Progress - Quiver Quantitative
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge - MarketBeat
Ligand tries to disembark from Viking pact, alleging breach - Fierce Biotech
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN) - The Globe and Mail
Viking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
VKTX SWOT Analysis: Financial Challenges and Promising Drug Pipe - GuruFocus
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN
Viking Therapeutics, Inc. Q1 2026 Financial Report: SEC 10-Q Filing, Financial Statements, and Key Disclosures - Minichart
Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says - marketscreener.com
Vanguard holds 5.88M Viking Therapeutics shares (NASDAQ: VKTX) in 13G - Stock Titan
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs - The Globe and Mail
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $71 to $125 - Moomoo
VKTX Maintains Overweight by Cantor Fitzgerald -- Price Target L - GuruFocus
Viking Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard (VKTX) - Seeking Alpha
Viking Therapeutics 1Q 2026: Revenue $0 Net loss $(158.3M), EPS $(1.37) — 10-Q Summary - TradingView
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX) Reports Progress in Obesity Drug Deve - GuruFocus
Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising R&D Costs - GuruFocus
Viking outlines 52-week VANQUISH extension and plans oral VK2735 phase III start in Q4 2026 - MSN
VKTX stock draws fresh attention ahead of earnings: Wall Street sees over 170% upside as GLP-1 race burns hot - MSN
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
Viking Therapeutics Q1 Earnings Call Highlights - MarketBeat
Viking Therapeutics (VKTX) Maintains Strong Financial Position A - GuruFocus
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):